Zobrazeno 1 - 10
of 257
pro vyhledávání: '"Sebastien J, Hotte"'
Autor:
Kim N. Chi, Steven M. Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K. Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J. Hotte, David T. Laidley, Fred Saad
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1400-1415 (2024)
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistan
Externí odkaz:
https://doaj.org/article/64b195e581c7483cb8fda268b1214380
Autor:
Esmail M. Al-Ezzi, Amer Zahralliyali, Aaron R. Hansen, Robert J. Hamilton, Michael Crump, John Kuruvilla, Lori Wood, Lucia Nappi, Christian K. Kollmannsberger, Scott A. North, Eric Winquist, Denis Soulières, Sebastien J. Hotte, Di Maria Jiang
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6166-6176 (2023)
Background: Although metastatic germ cell tumor (GCT) is highly curable with initial cisplatin-based chemotherapy (CT), 20–30% of patients relapse. Salvage CT options include conventional (CDCT) and high dose chemotherapy (HDCT), however definitive
Externí odkaz:
https://doaj.org/article/cdf6575c6dd6426a9ccb2edad31d8e08
Autor:
Kim A. Papp, Barbara Melosky, Sandeep Sehdev, Sebastien J. Hotte, Jennifer R. Beecker, Mark G. Kirchhof, Irina Turchin, Jan P. Dutz, Melinda J. Gooderham, Robert Gniadecki, Chih-ho Hong, Jo Lambert, Charles W. Lynde, Vimal H. Prajapati, Ronald B. Vender
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 4, Pp 867-889 (2023)
Abstract Background Patients with treated solid tumours (TSTs) are a highly heterogeneous population at an increased risk for malignancy compared with the general population. When treating psoriasis in patients with a history of TSTs, clinicians are
Externí odkaz:
https://doaj.org/article/062de13938e141a89117a95d3fedf09a
Autor:
Shawn Malone, Christopher J. D. Wallis, Richard Lee‐Ying, Naveen S. Basappa, Ilias Cagiannos, Robert J. Hamilton, Ricardo Fernandes, Cristiano Ferrario, Geoffrey T. Gotto, Scott C. Morgan, Christopher Morash, Tamim Niazi, Krista L. Noonan, Ricardo Rendon, Sebastien J. Hotte, Fred Saad, Anousheh Zardan, Brendan Osborne, Katherine F. Y. Chan, Bobby Shayegan
Publikováno v:
BJUI Compass, Vol 3, Iss 5, Pp 383-391 (2022)
Abstract Objectives To describe patterns of practice of PSA testing and imaging for Ontario men receiving continuous ADT for the treatment of non‐metastatic castration‐resistant prostate cancer (nmCRPC). Patients and Methods This was a retrospect
Externí odkaz:
https://doaj.org/article/3f6b6dfc44aa41928642415c19d064c2
Autor:
Kim A. Papp, Barbara Melosky, Sandeep Sehdev, Sebastien J. Hotte, Jennifer R. Beecker, Mark G. Kirchhof, Irina Turchin, Jan P. Dutz, Melinda J. Gooderham, Robert Gniadecki, Chih-ho Hong, Jo Lambert, Charles W. Lynde, Vimal H. Prajapati, Ronald B. Vender
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 8, Pp 1889-1890 (2023)
Externí odkaz:
https://doaj.org/article/7d190fe2e54149f09fa4e20f27e10e09
Autor:
Pei Jye Voon, Eric X. Chen, Helen X. Chen, Albert C. Lockhart, Solmaz Sahebjam, Karen Kelly, Ulka N. Vaishampayan, Vivek Subbiah, Albiruni R. Razak, Daniel J. Renouf, Sebastien J. Hotte, Arti Singh, Philippe L. Bedard, Aaron R. Hansen, S. Percy Ivy, Lisa Wang, Lee-Anne Stayner, Lillian L. Siu, Anna Spreafico
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-15 (2022)
Abstract Background Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D, maximum tolerated dose (MTD), and pharmacokinetic (PK) profile of trametini
Externí odkaz:
https://doaj.org/article/dfe80954e86a42808631f0fc9dd65391
Autor:
Giuseppe Procopio, Prabhu Bhagavatheeswaran, Bernard Escudier, Chung-Han Lee, Shruti Shally Saggi, Suresh Nair, Ruth Perets, Michael A Carducci, Vincent Castonguay, Edmund Folefac, Sebastien J. Hotte, Wilson H Miller,, Heshani Desilva
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Background The role and sequencing of combination immuno-oncology (IO) therapy following progression on or after first-line IO therapy has not been well-established. The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION)
Externí odkaz:
https://doaj.org/article/b2458af932914c44a5e2518aa22ce139
Stereotactic Body Radiation Therapy (SBRT) for a Patient with a Myocardial Metastasis: A Case Report
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 390-395 (2021)
Metastatic lesions of the heart are rare but have the potential to cause significant morbidity. We describe the case of a patient with renal cell carcinoma who presented with shortness of breath and palpitations and was found to have a metastatic myo
Externí odkaz:
https://doaj.org/article/91898bd9cb3c459faf440a539efefd51
Autor:
Suraya Bondy, Camilla Tajzler, Sebastien J. Hotte, Anil Kapoor, Kevin Zbuk, Aly-Khan A. Lalani
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 226-232 (2020)
Li-Fraumeni Syndrome (LFS) is defined by germline mutations of the p53 tumour suppressor gene. Adrenocortical carcinoma (ACC) is a rare aggressive malignancy that is commonly associated with LFS. Most LFS-linked ACC cases occur in children, and limit
Externí odkaz:
https://doaj.org/article/90bbdf57d20d41679c2492a1c8eb4310
Publikováno v:
Journal of Medical Case Reports, Vol 12, Iss 1, Pp 1-5 (2018)
Abstract Background Over the last 40 years, there has been a significant increase in the incidence of testicular cancer. The epidemiologic evidence to understand this phenomenon is unclear, however exogenous estrogen exposure is thought to be a drive
Externí odkaz:
https://doaj.org/article/88fe21b0191e40c7846906bcd13e551b